Ascentage Pharma Group Inc.
AAPG · China
Share price · AAPG
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AAPG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+11.8%
- 6 Oct 2026+10.2%
Nothing announced by AAPG that day or the session before.
- 27 Aug 2026+10.8%
Nothing announced by AAPG that day or the session before.
- 7 Aug 2026+11.1%
Nothing announced by AAPG that day or the session before.
- 17 Jul 2026-8.1%
Nothing announced by AAPG that day or the session before.
- 10 Jul 2026+5.7%
Nothing announced by AAPG that day or the session before.
- 23 Apr 2026-11.1%
- Day beforeREPORT OF FOREIGN PRIVATE ISSUER
- 1 Apr 2026+10.1%
- 27 Mar 2026+8.2%
- Day beforeREPORT OF FOREIGN PRIVATE ISSUER
- 23 Mar 2026+16.8%
Nothing announced by AAPG that day or the session before.
Share of unusual movement by asset
For each asset, the share of AAPG's own-move activity since 27 Jan 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FAK / ALK / ROS1Small molecule | Non-Small Cell Lung CancerOvarian Cancer | |
| Phase 3 | BCL-2Small molecule | Acute Myeloid LeukemiaMultiple MyelomaSystemic Lupus ErythematosusChronic Lymphocytic Leukemia Relapsed/Refractory Chronic Lymphocytic Leukemia | |
| Phase 3 | BCR-ABL (also AKT, c-Kit, ERK)Small molecule | Acute Myeloid LeukemiaChronic Myeloid Leukemia Chronic Myeloid Leukemia with T315I Mutation | |
| Phase 1/2 | MDM2Small molecule | Acute Myeloid Leukemia | |
| Phase 1 | Bcl-2 / Bcl-xLSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
2027 (5)
2028 (2)
May 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (1)
June 2029 (1)
What to watch
Financial reports
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $136M | $132M | $122M | $14M-$16M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-21 | Yang Dajun · director, Chairman and CEO | Option exercise | 95,575 | — | — | Form 4 |
| 2026-05-21 | Zhai Yifan · Chief Medical Officer | Option exercise | 92,746 | — | — | Form 4 |
| 2026-05-21 | Yang Dajun · director, Chairman and CEO | Option exercise | 92,746 | — | — | Form 4 |
| 2026-05-21 | Zhai Yifan · Chief Medical Officer | Option exercise | 95,575 | — | — | Form 4 |
| 2026-05-21 | Yang Dajun · director, Chairman and CEO | Option exercise (derivative) | 95,575 | — | — | Form 4 |
| 2026-05-21 | Zhai Yifan · Chief Medical Officer | Option exercise (derivative) | 92,746 | — | — | Form 4 |
| 2026-05-21 | Zhai Yifan · Chief Medical Officer | Option exercise (derivative) | 95,575 | — | — | Form 4 |
| 2026-05-21 | Yang Dajun · director, Chairman and CEO | Option exercise (derivative) | 92,746 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 0.0M shares ($722K).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | 16,056 | $383K |
| 2 | XY Capital Ltd | 13,014 | $311K |
| 3 | Tower Research Capital LLC (TRC) | 518 | $12K |
| 4 | MORGAN STANLEY | 498 | $12K |
| 5 | UBS Group AG | 124 | $3K |
| 6 | EverSource Wealth Advisors, LLC | 24 | $573 |
| 7 | ROYAL BANK OF CANADA | 6 | $0 |